| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514110800 | Parathyroid hormone (PTH) or derivative | 38 |
| 20110028394 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS - Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X | 02-03-2011 |
| 20110046059 | PHARMACEUTICALLY ACCEPTABLE FORMULATIONS/COMPOSITIONS FOR PEPTIDYL DRUGS - The present invention provides for pharmaceutically acceptable compositions for peptidyl drugs, method of making thereof, and methods of use thereof. Compositions are disclosed comprising a pharmaceutically effective amount of a peptidyl drug and a bioavailability enhancer in an amount sufficient to increase the bioavailability of the peptidyl drug. | 02-24-2011 |
| 20110059892 | Cosmetic preparations containing PTH fragments - A cosmetic or pharmaceutical composition includes a peptide parathyroid hormone fragment, derivatives thereof, salts thereof, and combinations thereof, where the peptide fragment conforms to the structure | 03-10-2011 |
| 20110071081 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 03-24-2011 |
| 20110092425 | METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN - The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients. | 04-21-2011 |
| 20110172153 | SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS - The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides. | 07-14-2011 |
| 20110172154 | PREVENTIVE AND/OR THERAPEUTIC AND/OR AGGRAVATION SUPPRESSING AGENT FOR HUMAN ARTHRITIS DEFORMANS - [Object] To provide a medicine that is extremely useful for preventing and/or treating and/or limiting exacerbation of human knee osteoarthritis. | 07-14-2011 |
| 20110178015 | METHODS OF TREATMENT USING BIASED LIGANDS FOR RECEPTORS SUCH AS THE PTH RECEPTOR - Disclosed are compositions and methods for modulating the β-arrestin pathway selectively over the G protein pathway of a G protein couple receptor, such as parathyroid hormone receptor. | 07-21-2011 |
| 20110178016 | PULSE PARATHYROID HORMONE FOR TREATMENT OF THE HEMATOPOIETIC SYNDROME, STROMAL CELL LOSS, AND VASCULAR INJURY RESULTING FROM ACUTE EXPOSURE TO LETHAL RADIATION - Currently there is no treatment for hematopoietic syndrome following radiation exposure. Exposed persons are presently treated with blood transfusions, growth factors such as G-CSF to promote neutrophil recovery. Present methods are targeted towards the bone marrow microenvironment, aiding in repair and regeneration with a decrease in the severity or possibly, complete avoidance of morbidity and mortality associated with the hematopoietic syndrome. Methods are useful for treatment of mass casualties following a radiation disaster. | 07-21-2011 |
| 20110195900 | PEPTIDIC PTH RECEPTOR AGONISTS - Novel peptidic pth receptor agonists and methods of using the same are provided. | 08-11-2011 |
| 20110224142 | PARATHYROID HORMONE RECEPTOR ACTIVATION AND STEM AND PROGENITOR CELL EXPANSION - The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells. | 09-15-2011 |
| 20110251124 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 10-13-2011 |
| 20120021986 | PROTECTING AND REPAIRING CARTILAGE AND MUSCULOSKELETAL SOFT TISSUES - Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor. | 01-26-2012 |
| 20120088725 | 5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS - Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided. | 04-12-2012 |
| 20120135930 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR - Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2-propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described. | 05-31-2012 |
| 20120178688 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS - Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X | 07-12-2012 |
| 20120232011 | Use of Rapamycin and Rapamycin Derivatives for the Treatment of Bone Loss - The present invention relates to a new use of rapamycin and rapamycin derivatives. | 09-13-2012 |
| 20120252729 | PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS - A method of treating osteoporosis by PTH that has excellent safety and high efficacy is disclosed, along with a method for inhibiting/preventing bone fractures by PTH that has excellent safety, as well as providing a drug to do this. A drug containing PTH as the active ingredient is disclosed, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method. | 10-04-2012 |
| 20130012440 | PREVENTIVE AND/OR THERAPEUTIC AND/OR AGGRAVATION SUPPRESSING AGENT FOR HUMAN ARTHRITIS DEFORMANS - A medicine that is extremely useful for preventing and/or treating osteoarthritis, which includes a parathyroid hormone (PTH), and methods of use of such medicine. | 01-10-2013 |
| 20130116180 | PARATHYROID HORMONE ANALOGS AND USES THEREOF - Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed. | 05-09-2013 |
| 20130150297 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS - Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X | 06-13-2013 |
| 20130157955 | METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN - The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients. | 06-20-2013 |
| 20130217630 | PARATHYROID HORMONE VARIANTS AND ASSAYS RELATED TO DISEASE - The invention relates to PTH variants and uses thereof in the detection, diagnosis, and treatment of various disease states. | 08-22-2013 |
| 20130288969 | PARATHYROID HORMONE RECEPTOR ACTIVATION AND STEM AND PROGENITOR CELL EXPANSION - The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells. | 10-31-2013 |
| 20140066376 | PROTECTING AND REPAIRING CARTILAGE AND MUSCULOSKELETAL SOFT TISSUES - Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor. | 03-06-2014 |
| 20140088014 | FREEZE-DRIED PREPARATION CONTAINING HIGH-PURITY PTH AND METHOD FOR PRODUCING SAME - [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. | 03-27-2014 |
| 20140249084 | PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS - [Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method. | 09-04-2014 |
| 20140256632 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 09-11-2014 |
| 20140315809 | CALCIMIMETICS AND METHODS FOR THEIR USE - Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR). | 10-23-2014 |
| 20140357560 | PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS - [Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. | 12-04-2014 |
| 20140378382 | ALPHA-/BETA-POLYPEPTIDE ANALOGS OF PARATHYROID HORMONE (PTH) AND METHOD OF USING SAME - Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent β-amino acid residues in place of a naturally occurring α-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism. | 12-25-2014 |
| 20150011473 | STABILIZED PTH FORMULATION - Stable pharmaceutical formulations comprising human parathyroid hormone are provided. The stabilized aqueous pharmaceutical formulation comprises human parathyroid hormone and a buffer selected from lactate or glutamate. In another embodiment a stabilized aqueous pharmaceutical formulation comprising human parathyroid hormone selected from the group of (1-34), (1-37), (1-38), (1-41), a buffer selected from lactate or glutamate, a stabilizing agent and a parenterally acceptable preservative, wherein the said formulation is sterile and ready for parenteral administration and having pH in the range of 3 to 7 is provided. | 01-08-2015 |
| 20150141339 | TREATMENT OF OSTEOPOROSIS - According to the invention there is provided a compound of formula (I): wherein R | 05-21-2015 |
| 20160151393 | PULMONARY PHARMACEUTICAL FORMULATIONS | 06-02-2016 |
| 20160159860 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS - Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X | 06-09-2016 |
| 20160175383 | CALCIMIMETICS AND METHODS FOR THEIR USE | 06-23-2016 |
| 20160184287 | TREATMENT FOR NICOTINE-INDUCED LUNG DISEASE USING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS - This invention pertains to the discovery that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine. | 06-30-2016 |
| 20180022777 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | 01-25-2018 |
